Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min, Stephen C. Bain
Diabetes Therapy (2020) Vol. 12, Iss. 1, pp. 143-157
Open Access | Times Cited: 207

Showing 1-25 of 207 citing articles:

Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 398
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 214
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 184
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise, Andrea Mari, J. Hans DeVries, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 418-429
Closed Access | Times Cited: 166
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, et al.
Molecules (2022) Vol. 27, Iss. 13, pp. 4315-4315
Open Access | Times Cited: 122
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
Tirzepatide: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 11, pp. 1213-1220
Closed Access | Times Cited: 86
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
Takashi Kadowaki, Rina Chin, Akichika Ozeki, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 9, pp. 634-644
Open Access | Times Cited: 85
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 82
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 61
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Leili Gao, Byung‐Wan Lee, Manoj Chawla, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1500-1510
Open Access | Times Cited: 50
Adverse Events Related to Tirzepatide
Rahul Mishra, Rishi Raj, Ghada Elshimy, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 46
2022 FDA TIDES (Peptides and Oligonucleotides) Harvest
Othman Al Musaimi, Danah Al Shaer, Fernando Alberício, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 336-336
Open Access | Times Cited: 41
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 22
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
Obesity management: sex-specific considerations
Tobias Kantowski, Clarissa Schulze zur Wiesch, Jens Aberle, et al.
Archives of Gynecology and Obstetrics (2024) Vol. 309, Iss. 5, pp. 1745-1752
Open Access | Times Cited: 18
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
Hannah Moll, E.A. Frey, Philipp A. Gerber, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102661-102661
Open Access | Times Cited: 18
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Tirzepatide: A Review in Type 2 Diabetes
Nicole L. France, Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 2, pp. 227-238
Closed Access | Times Cited: 16
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
Ewelina Młynarska, Witold Czarnik, Natasza Dzieża, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1094-1094
Open Access | Times Cited: 4
Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives
Walter Cabri, Paolo Cantelmi, Dario Corbisiero, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 93
Page 1 - Next Page

Scroll to top